DIM Stock Analysis: Sartorius Stedim Biotech | PA
Medical Instruments & Supplies | PA, France | Market Cap: 17.444m EUR | 12M Return: -10.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 13.6M
EPS Trend: -31.9%
Qual. Beats: 0
Rev. Trend: 6.4%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Sartorius Stedim Biotech S.A. (DIM) is a French-headquartered supplier of instruments and consumables for the global biopharmaceutical industry, operating as a subsidiary of Germanys Sartorius AG. Its product portfolio spans the full bioprocessing workflow, including cell lines, cell culture media, bioreactors, reagents, advanced therapy solutions, and systems for separation, purification, concentration, storage, and transport of biological products. The company also provides a wide range of lab-scale equipment and software tools - covering fluid management, biosensors, chromatography, pipettes, imaging, data analytics, and process automation - making it a one-stop vendor for biopharma manufacturers, vaccine producers, and R&D laboratories.
The business model is fundamentally B2B, selling critical inputs and equipment to drug manufacturers and research institutions rather than end patients. The bioprocessing sector is characterized by high regulatory barriers and long customer qualification cycles, which tend to create recurring revenue streams from consumables and aftermarket services. The company is also expanding its geographic reach, notably through a collaboration with Bio Usawa Biotechnology to develop and manufacture monoclonal antibodies in Sub-Saharan Africa for oncology, infectious, and autoimmune diseases.
- Single-use bioprocessing demand weakens on biopharma destocking
- Margin compression from raw materials and competitive pricing pressures
- Cell and gene therapy adoption advances long-term consumables revenue
| Net Income: 268.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -4.43 > 1.0 |
| NWC/Revenue: 1.39% < 20% (prev 28.53%; Δ -27.14% < -1%) |
| CFO/TA 0.07 > 3% & CFO 610.5m > Net Income 268.1m |
| Net Debt (2.27b) to EBITDA (842.7m): 2.69 < 3 |
| Current Ratio: 1.03 > 1.5 & < 3 |
| Outstanding Shares: last quarter (97.3m) vs 12m ago 0.02% < -2% |
| Gross Margin: 44.71% > 18% (prev 43.89%; Δ 0.82% > 0.5%) |
| Asset Turnover: 36.19% > 50% (prev 34.42%; Δ 1.77% > 0%) |
| Interest Coverage Ratio: 2.96 > 6 (EBIT TTM 520.9m / Interest Expense TTM 175.8m) |
| A: 0.01 (Total Current Assets 1.65b - Total Current Liabilities 1.61b) / Total Assets 8.19b |
| B: 0.33 (Retained Earnings 2.66b / Total Assets 8.19b) |
| C: 0.06 (EBIT TTM 520.9m / Avg Total Assets 8.25b) |
| D: 1.02 (Book Value of Equity 4.11b / Total Liabilities 4.05b) |
| Altman-Z'' = 2.58 = A |
| DSRI: 1.09 (Receivables 302.8m/267.0m, Revenue 2.98b/2.86b) |
| GMI: 0.98 (GM 43.89% / 44.71%) |
| AQI: 0.99 (AQ_t 0.55 / AQ_t-1 0.55) |
| SGI: 1.04 (Revenue 2.98b / 2.86b) |
| TATA: -0.04 (NI 268.1m - CFO 610.5m) / TA 8.19b) |
| Beneish M = -2.95 (Cap -4..+1) = A |
As of July 11, 2026, the stock is trading at EUR 183.30 with a total of 71,730 shares traded. Over the past week, the price has changed by +1.72%, over one month by +2.63%, over three months by +7.63% and over the past year by -10.53%.
Current recommended Stop Loss: 175.80 (which is 4.1% or 1.2 ATR below the current price).
Sartorius Stedim Biotech has no consensus analysts rating.
P/E Trailing = 64.9638
P/E Forward = 36.7647
P/S = 5.8451
P/B = 4.2673
P/EG = 1.5228
Revenue TTM = 2.98b EUR
EBIT TTM = 520.9m EUR
EBITDA TTM = 842.7m EUR
Long Term Debt = 1.86b EUR (from longTermDebt, last quarter)
Short Term Debt = 605.7m EUR (from shortTermDebt, last quarter)
Debt = 2.79b EUR (from shortLongTermDebtTotal, last quarter) + Leases 172.4m
Net Debt = 2.27b EUR (calculated: Debt 2.79b - CCE 521.2m)
Enterprise Value = 19.7b EUR (17.4b + Debt 2.79b - CCE 521.2m)
Interest Coverage Ratio = 2.96 (Ebit TTM 520.9m / Interest Expense TTM 175.8m)
EV/FCF = 92.54x (Enterprise Value 19.7b / FCF TTM 213.0m)
FCF Yield = 1.08% (FCF TTM 213.0m / Enterprise Value 19.7b)
FCF Margin = 7.14% (FCF TTM 213.0m / Revenue TTM 2.98b)
Net Margin = 8.98% (Net Income TTM 268.1m / Revenue TTM 2.98b)
Gross Margin = 44.71% ((Revenue TTM 2.98b - Cost of Revenue TTM 1.65b) / Revenue TTM)
Gross Margin QoQ = 45.36% (prev 41.04%)
Tobins Q-Ratio = 2.41 (Enterprise Value 19.7b / Total Assets 8.19b)
Interest Expense / Debt = 6.31% (Interest Expense 175.8m / Debt 2.79b)
Taxrate = 28.73% (108.3m / 376.9m)
NOPAT = 371.2m (EBIT 520.9m * (1 - 28.73%))
Current Ratio = 1.03 (Total Current Assets 1.65b / Total Current Liabilities 1.61b)
Debt / Equity = 0.68 (Debt 2.79b / totalStockholderEquity, last quarter 4.11b)
Debt / EBITDA = 2.69 (Net Debt 2.27b / EBITDA 842.7m)
Debt / FCF = 10.64 (Net Debt 2.27b / FCF TTM 213.0m)
Total Stockholder Equity = 4.06b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.25% (Net Income 268.1m / Total Assets 8.19b)
RoE = 6.60% (Net Income TTM 268.1m / Total Stockholder Equity 4.06b)
RoCE = 8.80% (EBIT 520.9m / Capital Employed (Equity 4.06b + L.T.Debt 1.86b))
RoIC = 5.28% (NOPAT 371.2m / Invested Capital 7.04b)
WACC = 7.16% (E(17.4b)/V(20.2b) * Re(7.59%) + D(2.79b)/V(20.2b) * Rd(6.31%) * (1-Tc(0.29)))
Discount Rate = 7.59% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 31.46 | Cagr: 2.44%
[DCF] Terminal Value 73.10% ; FCFF base≈361.2m ; Y1≈316.8m ; Y5≈255.9m
[DCF] Fair Price = 18.94 (EV 4.11b - Net Debt 2.27b = Equity 1.84b / Shares 97.3m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -31.94 | EPS CAGR: -7.44% | SUE: -0.28 | # QB: 0
Revenue Correlation: 6.44 | Revenue CAGR: 0.33% | SUE: -0.06 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.28 | Chg30d=+0.16% | Revisions=-25% | Analysts=3
EPS next Quarter (2026-09-30): EPS=1.22 | Chg30d=-0.25% | Revisions=-25% | Analysts=3
EPS current Year (2026-12-31): EPS=5.06 | Chg30d=+0.29% | Revisions=+50% | GrowthEPS=+15.0% | GrowthRev=+6.7%
EPS next Year (2027-12-31): EPS=6.01 | Chg30d=-0.62% | Revisions=+40% | GrowthEPS=+18.9% | GrowthRev=+10.4%
[Analyst] Revisions Ratio: +30% (up=5, down=2)